<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03061396</url>
  </required_header>
  <id_info>
    <org_study_id>2014CB543201-03</org_study_id>
    <nct_id>NCT03061396</nct_id>
  </id_info>
  <brief_title>The Comparative Study on the Efficacy and Safety of Single Acupoint and Matching Acupoints</brief_title>
  <official_title>The Different Effectiveness of Single Acupoint vs Matching Acupoints in Chemotherapy-induced Nausea and Vomiting：A Multicenter, Randomized, Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Basic Research Program, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gansu Provincial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin University of Traditional Chinese Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to clarify whether the matching acupoints are more effective
      than a single point by electro-acupuncture in the management of chemotherapy-induced nausea
      and vomiting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2017</start_date>
  <completion_date type="Anticipated">May 28, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Control rates of Nausea and Vomiting</measure>
    <time_frame>6weeks</time_frame>
    <description>There is no emetic episodes, no rescue therapy, and no significant nausea from first day of antiemetic therapy to 5th day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Response rates of Vomiting</measure>
    <time_frame>6weeks</time_frame>
    <description>There is no emetic episodes and no rescue therapy on first day of antiemetic therapy and second day to 5th day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nausea and Vomiting visual analogic scale (VAS)</measure>
    <time_frame>6weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tcm Gastro-intestinal evaluation</measure>
    <time_frame>3weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the grading of constipation ,diarrhea and decrease in appetite</measure>
    <time_frame>3weeks</time_frame>
    <description>Number of participants with constipation ,diarrhea and decrease events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrogastrogram</measure>
    <time_frame>3weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale</measure>
    <time_frame>3weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Treatment - General scale4.0</measure>
    <time_frame>3weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Abnormal Laboratory Values</measure>
    <time_frame>6weeks</time_frame>
    <description>the number of blood cells,serumAlanine aminotransferase,Aspertate，Aminotransferase,total bilirubin,Creatinine，blood sodium，blood potassium</description>
  </other_outcome>
  <other_outcome>
    <measure>cardial electrical activity</measure>
    <time_frame>6weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>other adverse effect during the chemotherapy</measure>
    <time_frame>6weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Electro-acupuncture</condition>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Electroacupuncture Single point</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single point PC6 means there is only one acupoint to be chosen: Neiguan(PC6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Electroacupuncture Matching points</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There are three acupoints to be chosen:Bilateral Neiguan(PC6)and Zhongwan(CV12)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching points PC6+CV12</intervention_name>
    <description>Choose both Neiguan(PC6) and Zhongwan point(CV12).The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.</description>
    <arm_group_label>Electroacupuncture Matching points</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Single points PC6</intervention_name>
    <description>Choose Neiguan(PC6)of double upper limb.The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.</description>
    <arm_group_label>Electroacupuncture Single point</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be diagnosed as cancer and need to accept chemotherapy

          2. The score of Karnofsky ≥70

          3. Patients of either gender and age 18 years to 80 years

          4. Patients receiving chemotherapy both outpatients and inpatients

          5. Patients receiving chemotherapy regime with high risk of causing vomiting: cisplatin
             ≥60 mg/m2, or joint chemotherapy regime of Anthracyclines (Adriamycin≥ 40 mg/ m2 or
             epirubicin≥60 mg/m2), Dacarbazine or Carboplatin（area under the curve greater than
             5mg/ml/min）

          6. Life expectancy ＞ 6 months

        Exclusion Criteria:

          1. To receive radiotherapy and chemotherapy

          2. Gastrointestinal tumors

          3. Patients with serious liver disease or abnormal hepatorenal function (Aspartate
             Aminotransferase, Alanine Aminotransferase , and Total Bilirubin are 3 times more than
             normal, blood urea nitrogen and Cr are 2 times more than normal)

          4. Presence of cardiac pacemaker

          5. Inflammatory skin reaction

          6. Nausea and/or vomiting resulting from opioids or metabolic imbalance (electrolytic
             disturbances)

          7. Patients unable to provide self-care or communication

          8. Nausea and/or vomiting resulting from mechanical risk factors (i.e.,intestinal
             obstruction)

          9. Patients with brain metastases or symptoms of intracranial hypertension

         10. Nausea and/or vomiting resulting from other diseases(i.e.,sympathetic cervical
             dispositions, Meniere's syndrome)

         11. Women in pregnant and lactating period

         12. Refusal to sign informed consent, rejection of randomization into intervention groups.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tianjin University of TCM</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300193</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guo Yi, Doc</last_name>
      <phone>13920921016</phone>
      <email>tjutcmacupuncture@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2017</study_first_submitted>
  <study_first_submitted_qc>February 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Yi Guo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

